Full Press Release Details
Third quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the second quarter of 2026, primarily driven by growth in Corexa Pharmacy drug dispensing
Launch of the Health Lives Here mobile app, partnered with the NFL Alumni Health marketing platform, gives Corexa Pharmacy a unique customer acquisition channel to dispense FDA-approved GLP-1 medications and the medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies
Exclusive license to the REBOOT GLP-1 patient management platform and intellectual property creates moat to scale customer acquisition and increase long-term customer value through patented, AI-assisted patient management services
Corexa Pharmacy launch of compounded peptides under FDA’s Enforcement Discretion Policy adds an incremental revenue opportunity
MOU with HMO to deploy the Health Lives Here mobile app to 25,000+ members provides institutional customer to optimize PMPM model institutional customers
Acquisition of Helomics cancer diagnostics laboratory, coupled with Humana Medicaid coverage for proprietary ChemoFx® Assay, adds incremental proprietary revenue stream, in addition to traditional lab services revenue, and opens cancer pharmaceuticals market for Corexa Pharmacy
Company regains full compliance with Nasdaq listing standards
Tampa, Fla. – Monday, November 16, 2026 - DataMEDS AI, Inc. (“DataMEDS AI,” “DataMEDS” or the “Company”) (NASDAQ: MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.
“Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions,” said Gerald Commissiong, Interim Co-CEO of DataMEDS. “Health Lives Here, backed by NFL Alumni Health, brings patients to Corexa Pharmacy. The REBOOT license gives us patented, AI-assisted tools to keep GLP-1 patients engaged, proprietary Tollo Health medical foods for muscle loss associated with weight loss therapies gives them unique tools to mitigate the drugs’ side effects and Helomics adds diagnostic testing revenue streams. With our first HMO relationship and compounded peptides opening new channels, and full Nasdaq compliance restored, we believe DataMEDS is well positioned for continued growth going forward.”
-1-
Business Update
Health Lives Here and NFL Alumni Health. The Company launched the Health Lives Here mobile application, partnered with the NFL Alumni Health marketing platform. The app gives Corexa Pharmacy a unique customer acquisition channel to dispense FDA-approved GLP-1 medications and Forzet™, a medical food for the dietary management of muscle loss associated with weight loss therapies.
REBOOT GLP-1 license. In October 2026, DataMEDS obtained an exclusive license to the REBOOT GLP-1 patient management platform and related intellectual property. The Company believes these patented, AI-assisted patient management services create a moat that supports scaling customer acquisition and increasing long-term customer value.
Compounded peptides. In November 2026, Corexa Pharmacy launched compounded peptides under FDA’s Enforcement Discretion Policy published in the Federal Register on October 30, 2026, adding an incremental revenue opportunity. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or efficacy.
First HMO relationship. In November 2026, the Company signed a non-binding memorandum of understanding with a Florida-based HMO to deploy the Health Lives Here app to its 25,000+ members, providing a platform to optimize user engagement for an institutional customer base. Definitive agreements are expected in the fourth quarter of 2026.
Helomics. In September 2026, DataMEDS acquired Helomics Corporation, a Pittsburgh-based CLIA-certified cancer diagnostics laboratory. Humana’s South Carolina Medicaid coverage policy for the proprietary ChemoFx® Assay, effective July 22, 2026, adds an incremental proprietary revenue stream and opens the cancer pharmaceuticals market for Corexa Pharmacy. Additionally, Helomics’ biobank of 70,000+ primary tumor biopsies creates drug discovery opportunities. The Company is adding additional testing services to Helomics’ test menu to allow it to support patient groups beyond cancer, especially GLP-1 patients.
Nasdaq compliance. On October 19, 2026, the Company regained full compliance with Nasdaq listing standards, including the net equity requirement.
Profit from Operations:
The Company recorded a net operating profit of $10.535 million in the quarter ended September 30, 2026, compared with a net operating loss of $34.318 million in the quarter ended September 30, 2025. The net profit in the third quarter of 2026 as compared with the net loss in the third quarter of 2025 loss was largely due to the extinguishment of debt and outstanding liabilities related to litigation associated with prior management and a reduction in expenses associated management compensation, as well as a reduction in general and administrative expenses. Net profit per share in the quarter ended September 30, 2026 was $2.72 on 3.961 million weighted average shares outstanding, compared to the quarter ended September 30, 2025, where the Company delivered a loss of $23.07 per share on 1.488 million weighted average shares outstanding.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.
For more information on DataMeds Ai, Inc., refer to www.datamedsai.com.
About DataMEDS AI
DataMEDS AI, Inc. (NASDAQ: MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. Learn more at https://datamedsai.com.
-2-
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding: the Company’s future revenue growth and financial results, including whether Corexa Pharmacy dispensing revenue continues to grow; customer acquisition through the Health Lives Here app and the NFL Alumni Health marketing platform, and related-party arrangements with Tollo Health, LLC; the scope, enforceability and competitive value of the REBOOT license and related intellectual property; Corexa Pharmacy’s ability to compound and dispense peptides in compliance with FDA’s Enforcement Discretion Policy and state pharmacy laws, and the possibility that the policy is changed or withdrawn; the non-binding nature of the HMO memorandum of understanding and the possibility that definitive agreements are not executed on the expected timeline or at all; the integration of Helomics and its ability to grow ChemoFx testing volumes and reimbursement; demand for GLP-1 medications and Forzet™ and the regulatory status of medical foods; compliance with healthcare laws, including federal and state anti-kickback, beneficiary inducement and privacy laws; the Company’s ability to maintain compliance with Nasdaq listing standards; and the Company’s liquidity, capital resources and ability to fund operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
DataMEDS AI Media Contact
James Lambert, Vice President, Rubenstein Public Relations
212.805.3024 | jlambert@rubensteinpr.com
DataMEDS AI Investor Contact
-3-
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
DATAMEDS AI, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30, 2026 | December 31, 2025
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents | 476,598 | 42,571
Accounts receivable, net | 1,966,605 | 1,137,219
Inventories, net | 1,440,296 | 1,639,426
Due from related parties | 1,162,125
Prepaid and other current assets | 174,411
Total current assets | 5,220,035 | 2,819,216
Property, plant and equipment, net | 323,305 | 229,376
Capitalized software | 2,345,268 | 1,850,358
Operating lease, right-of-use-assets | 1,590,240 | 966,893
Goodwill | 15,787,176 | 14,193,923
Other intangible assets, net | 13,249,358 | 10,314,675
Investment in SAFE | 35,000
Deposits and other assets | 183,486 | 85,008
Total assets | 38,733,868 | 30,459,449
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable | 13,061,543 | 11,665,135
Accounts payable, related party | 25,500 | 25,500
Accrued expenses and other liabilities | 3,647,245 | 6,407,722
Purchase consideration liability | 1,885,700
Due to related parties | 225,000
Convertible notes payable, net of debt discount | 15,275,679
Current portion of debt obligations, net of debt discount | 2,788,058 | 10,887,520
Operating lease liabilities- current portion | 1,229,731 | 569,251
Total current liabilities | 37,913,456 | 29,780,128
Note payable, net of discount | 100,000 | 12,600,000
Operating lease liabilities | 548,717 | 527,122
Total liabilities | 38,562,173 | 42,907,250
Commitments and contingencies (Note 15)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value, 500,000,000 shares authorized, 4,740,862 and 4,730,148 shares issued and 2,836,484 and 2,026,150 shares outstanding as of September 30, 2026 and December 31, 2025, respectively | 473 | 203
Additional paid-in capital | 124,851,605 | 98,583,686
Accumulated deficit | (126,547,748 | (111,031,690
Total DataMeds AI, Inc. stockholders’ equity (deficit) | (1,695,670 | (12,447,801
Non-controlling interest | 1,867,365
Total stockholders’ equity (deficit) | 171,695 | (12,447,801
Total liabilities and stockholders’ equity (deficit) | 38,733,868 | 30,459,449
-4-
DATAMEDS AI, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended | Nine Months Ended
September 30, | September 30,
2026 | 2025 | 2026 | 2025
Net revenues | 2,668,980 | 3,012,904 | 6,008,403 | 21,667,212
Cost of net revenues | 2,237,100 | 2,781,892 | 5,224,098 | 20,237,807
Gross profit (loss) | 431,880 | 231,012 | 784,305 | 1,429,405
Operating expenses:
General and administrative | 3,343,627 | 30,172,800 | 15,269,233 | 66,205,669
Sales and marketing | 105,788 | 803,747 | 1,179,778 | 1,212,347
Depreciation and amortization | 356,421 | 802,794 | 1,069,842 | 2,408,462
Total operating expenses | 3,805,836 | 31,779,341 | 17,518,853 | 69,826,478
Loss from operations | (3,373,956 | (31,548,329 | (16,734,548 | (68,397,073
Other income (expense):
Interest expense, net | (2,252,401 | (1,425,307 | (5,886,320 | (3,703,837
Loss on extinguishment of vendor obligation | (3,605,978 | (3,666,098
Gain (loss) on extinguishment of debt | 19,064,881 | (1,353,663 | 10,183,187 | (1,353,663
Loss on contract termination fee | (766,394
Settlement fees | (13,000
Other income | 703,014 | 9,095 | 1,312,911 | 33,002
Total other income (expense), net | 13,909,516 | (2,769,875 | 1,164,286 | (5,024,498
Net income (loss) before income taxes | 10,535,560 | (34,318,204 | (15,570,262 | (73,421,571
Provision for income taxes
Net income (loss) | 10,535,560 | (34,318,204 | (15,570,262 | (73,421,571
Net loss attributable to non-controlling interest | (54,204 | (54,204
Net income (loss) attributable to DataMeds AI | 10,589,764 | (34,318,204 | (15,516,058 | (73,421,571
Weighted average common shares outstanding - basic and diluted
Basic | 3,214,663 | 1,487,588 | 2,636,382 | 1,249,164
Diluted | 3,961,210 | 1,487,588 | 2,636,382 | 1,249,164
Net loss per common share - basic and diluted
Basic | 3.29 | (23.07 | (5.89 | (58.78
Diluted | 2.72 | (23.07 | (5.89 | (58.78
-5-